Gilead Sciences Aktie News

Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “The ac...

Among Wall Street stocks, some of the best opportunities can be found in reliable companies trading at a discount. With such undervalued stocks, investors get a strong foundation for their portfolio along with potential for positive returns.

Walgreens is still reeling from years of mismanagement. Gilead Sciences looks reliable, but is growing slowly.

With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2024 financial results and provide a business upd...

AbbVie offers one of the most attractive dividends around. Gilead Sciences provides stability and consistency to income investors.

Starbucks, BCE, and Gilead Sciences pay dividends that yield well above the S&P 500 average. These companies all have strong businesses that can make for ideal long-term investments.